This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Star Scientific, Inc. Sued By Investor

Stocks in this article: STSI

SAN DIEGO and GLEN ALLEN, Va., April 2, 2013 /PRNewswire/ --  Shareholder rights attorneys at Robbins Arroyo LLP announce that a purchaser of Star Scientific, Inc. (NASDAQ: STSI) securities has filed a complaint in the U.S. District Court for the Eastern District of Virginia.  The complaint alleges that Star Scientific and certain of its officers and directors violated the Securities Exchange Act of 1934 between October 31, 2011 and March 18, 2013 (the "Class Period").  

(Logo:  http://photos.prnewswire.com/prnh/20130103/MM36754LOGO)  

Star Scientific Accused of Making False and Misleading Statements Concerning the Company's Business, Operational, and Compliance Policies

The complaint alleges that the Star Scientific, a drug manufacturing company that produces products to promote a healthy lifestyle, such as dietary supplements, issued a series of materially false and misleading statements to investors regarding the company's business, operational, and compliance policies.  Specifically, the complaint alleges that certain officers and directors delayed disclosure of the fact that the company had received subpoenas from the U.S. Attorney's office investigating potential securities fraud in Star Scientific's securities involving transactions dating back to 2006.  

Star Scientific Price Drops Multiple Times: Concerned Shareholder Respond with Lawsuit

Further, Star Scientific, through its subsidiary Rock Creek, issued multiple press releases from 2011 through 2013, which led investors to believe that researchers at Johns Hopkins University had an active role in the clinical testing of its retail nutritional supplement anatabine. However, on January 23, 2013, The Street published an article alleging that the company misled investors regarding the role of John Hopkins University in the clinical testing of anatabine. The article quoted Johns Hopkins school of Medicine spokesperson Stephanie Desmon as stating, "The … clinical study was not conducted at or approved by Johns Hopkins." On this news, Star Scientific's stock declined $0.31 per share or nearly 12%, to close at $2.33 per share on January 23, 2013.

Moreover, in January and February 2013, Star Scientific received subpoenas from the U.S. Attorney's office for the Eastern District of Virginia concerning an investigation into whether the company engaged in potentially illegal transactions involving certain private placements and related party transactions since 2006.  Star Scientific failed to disclose this investigation to investors until March 18, 2013, at which time the company announced it was conducting an internal investigation.  As a result, Star Scientific shares declined a further $0.35 per share or 18% to $1.63 on March 19, 2013.

If you purchased or otherwise acquired Star Scientific stock during the Class Period and wish to serve as lead plaintiff, you must act no later than May 24, 2013.  To discuss your shareholder rights, please contact attorney Darnell R. Donahue at (800) 350-6003, ddonahue@robbinsarroyo.com, or via the shareholder information form on the firm's website. 

Robbins Arroyo LLP is a nationally recognized leader in securities litigation and shareholder rights law.  The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.  For more information, please go to http://www.robbinsarroyo.com.

Press release link: http://www.robbinsarroyo.com/shareholders-rights-blog/star-scientific-inc/

Attorney Advertising. Past results do not guarantee a similar outcome.  

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs